Objectives-To determine whether polymorphisms of the TAP genes, which lie within the major histocompatibility complex (MHC), are associated with juvenile chronic arthritis (JCA). Methods-Eighty five JCA patients and 166 white controls were typed for the TAP gene alleles using ARMS-PCR. The same populations were analysed for DRBI and DPB1 alleles using PCR-SSO typing. Results-TAP2B was increased in early onset pauciarticular JCA (EOPA-JCA) compared with controls (62% v 44% Odds ratio (OR) 2-1, 95% CI 0-9-4-7). After allowing for the known linkage disequilibrium between TAP2B and DRI the association of TAP2B and EOPA-JCA was maintained (OR 3*5, 95% CI 1-3-9.7). 
HLA-DRB1*04 and TAP2D were found to be in linkage disequilibrium in both the control (A 0-018 p < 0.05) and JCA patient groups (A 0-021 p < 0.05). No Polymorphisms of the TAP genes in the rat are more extreme than those recorded in humans and are functionally important, altering the identity of peptides found in association with class I molecules.8 Polymorphic variants of the human TAP genes might also act to influence the selection of peptides delivered to class I molecules and may disrupt the stability of the trimolecular unit formed between class I antigen, b2 microglobulin and peptide fragment. Any change to the antigen presenting complex could result in an alteration of T cell response.
The TAP genes represent candidate disease susceptibility genes for JCA and they may further delineate the HLA haplotypes associated with this condition. We have therefore investigated TAP1 and TAP2 polymorphisms in different clinical subgroups ofJCA.
Materials and methods

PATIENTS AND CONTROLS
Five mls of blood were taken into EDTA tubes with the consent of all patients and controls included in the study. The patient and the control populations were both from the Greater Manchester area.
Eighty five white patients conforming to the criteria or JCA9 were classified into subgroups based on the number of joints affected at disease onset plus any evidence of systemic disease features. The subgroups involved in the study were as follows: early onset pauciarticular (EOPA) (n = 29), .four joints affected and onset before the age of six years. Late onset pauciarticular (LOPA) (n = 24), <four joints affected and onset after the age of six years. Polyarticular (PLY) (n = 17), >five joints affected at onset. Systemic onset (SO) (n = 17), pyrexia and classic Still's rash at presentation. The control population consisted of 166 randomly selected healthy UK white group. Of our 29 EOPA-JCA patients the female to male ratio was 2:1, 41% were ANA positive and five had a history of chronic anterior uveitis. None had a family history of psoriasis. In 26 the outcome at one year was known, and of these, five had extended to polyarticular disease. DNA 
EXTRACTION
Genomic DNA was extracted from whole blood using a standard, automated, phenolchloroform extraction procedure. We have now found a weak association between TAP2B and EOPA. In a previously reported smaller number of the same population of EOPA JCA patients, the trend towards an increase in TAP2B was present. '4 TAP2B has been shown to be in strong linkage disequilibrium with DR1.'2 Whilst DR1 is raised in LOPA it is not found at an increased frequency in EOPA. As expected therefore after analysing DR1 negative EOPA patients and controls, the increase in TAP2B was found not to be dependent on any linkage disequilibrium with DR1.
The TAP genes were not found to be raised or lowered in any other JCA subgroup. The only positive linkage disequilibrium found was that between DR4 and TAP2D, occurring in both the JCA and control populations. ' There was difficulty in assigning TAPI alleles to all patients in our study, as those typing heterozygous (isoleucine/valine) at aa position 333 and heterozygous (aspartic acid/ glycine) at aa position 637 could be either TAP1A/TAP1B or TAPIC/TAPlD. Based on the individual allele frequencies these individuals will most likely be TAP 1AITAP1B, and we are currently examining families to establish the pattern of segregation. From the gene frequencies in our JCA patient population, however, there is no increase in valine/valine homozygotes (aa 333)/glycine/glycine homozygotes (aa 637) compared with controls.
In conclusion, it would appear that the increase in TAP2B represents another association with EOPA JCA, not due to linkage disequilibrium with DRB1 or DPB1 alleles. This, together with the many other HLA antigens known to confer risk in EOPA, reinforces the apparent heterogeneity of this JCA subgroup. EOPA might itself be several disease entities with no unifying aetiology. It may be useful to look further at the TAP gene associations, both in larger numbers of ANA positive uveitis cases and in those EOPA patients which extend to polyarticular disease. Whilst the entire classification of JCA remains a difficult and controversial area it could be that the evolving immunogenetic profile of EOPA will help in the appraisal of the current clinically derived subgrouping.
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